New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
08:23 EDTKPTIKaryopharm data positive, says JMP Securities
JMP Securities notes that updated Phase I data for Karyopharm's Selinexor in AML show improved objective response rates over prior analysis. The firm finds the data increasingly encouraging, and believes it bodes well for a potential pivotal study in AML beginning in 1H14. The firm reiterates a $25 price target and Outperform rating on the stock.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
07:06 EDTKPTIKaryopharm announces Phase 1 trial of Selinexor
Subscribe for More Information
April 15, 2014
16:08 EDTKPTIKaryopharm announces initiation of Phase 1 study of Selinexor-decitabine combo
Karyopharm Therapeutics announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor in combination with the DNA methylation inhibitor decitabine in patients with relapsed or refractory acute myeloid leukemia, or AML, and in patients age 60 years with newly diagnosed AML. Sharon Shacham, Karyopharm's founder, President and Chief Scientific Officer, commented, "This first combination study of Selinexor represents a significant milestone for the company as we look to broaden the scope of SINE compounds in the treatment of cancers."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use